Galectin Therapeutics Inc. NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today ...

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs ...

At Galectin Therapeutics Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have report no sales in the last 30 days, meanwhile, insiders have reported buying a ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

在长期新冠患者的血液中，研究小组发现与全身炎症相关的蛋白质水平较高，尤其是galectin-9和artemin。Elahi表示，这两种蛋白质有助于解开长期新冠的谜团，因为患者体内galectin-9水平升高与炎症和脑雾加重有关，而artemin则与广泛疼痛、严重疼痛和认知损害相关。

Galectin-9 directly binds to arabinogalactan (AG), leading to the identification of AG-specific monoclonal antibodies that effectively inhibit Mycobacterium tuberculosis growth, providing insights for ...

Completed strategic review to focus on oncology and severe liver diseases- Announced acquisition of global rights to BRM-1420, a dual ...

中山大学第一附属医院张弩、刘雪松、张茂雷等人在 Cell 子刊 Cell Reports Medicine 上发表了题为 Lnc-H19-derived protein shapes the immunosuppressive ...

NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces ...